Clinical Trial Update: Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases [Phase 2]

View source ↗

Summary

Phase II trial of cobimetinib plus vemurafenib in patients with active melanoma brain metastases was terminated; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma Brain Metastases

Drugs mentioned

• Cotellic (cobimetinib)
• Zelboraf (vemurafenib)

Snippet

Sponsor: Melissa Burgess, MD | Conditions: Active Melanoma Brain Metastases | Phase 2 | Status: TERMINATED | Results posted: 2017-10-12